<DOC>
	<DOCNO>NCT00406523</DOCNO>
	<brief_summary>Janus stent market drug-eluting stent ( DES ) without polymer coating yet China . The goal study evaluate efficacy JANUS ( Tacrolimus elute stent ) inhibit restenosis percutaneous coronary intervention ( PCI ) real world observe safety efficacy 4 month ’ clopidogrel treatment implantation JANUS stent . Patients enrol randomize treated JANUS SRNCRO ( bare metal stent platform JANUS ) . All enrol patient receive daily clopidogrel 4 month aspirin life long post-PCI period ( In AMI group , patient receive daily clopidogrel 150mg 2 week first ) . The primary endpoint include death heart , myocardial infarction , revascularization target lesson , sub-acute late stent thrombosis one year PCI , The secondary endpoint include MACE 30 day , 6 month restenosis follow-up angiogram 6 12 month .</brief_summary>
	<brief_title>A Single Center Prospective Randomized Controlled Clinical Study JANUS Stent Patients With Coronary Artery Disease</brief_title>
	<detailed_description />
	<mesh_term>Heart Diseases</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<criteria>Patients eligible coronary stenting All patient enrol implanted one kind stent Stent number ≤ 8 per patient ≤3 per vessel ( stent overlap part 3～5mm fully postdilated ; Total stent length ≤ 85mm vessel ) Willing able sign inform consent . Patients multivessel disease could implant kind stent Instent restenosis target lesion Patients eligible DES implantation ( e.g . intolerance antiplatelet therapy undergoing heart nonheart surgery recently</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2006</verification_date>
</DOC>